TABLE 4.
Stem cell therapy in clinical trials for Alzheimer's disease (ClinicalTrials.gov accessed January 1, 2023).
| Agent | Phase | Clinical trial NCT# | Sponsor | Start date | Primary completion date |
|---|---|---|---|---|---|
| Allogenic human mesenchymal stem cells | Phase 2 | NCT02833792 | Stemedica Cell Technologies, Inc. | 2016‐06‐01 | 2024‐07‐30 |
| Amniotic and umbilical cord tissue | Phase 1 | NCT03899298 | R3 Stem Cell | 2019‐09‐01 | 2024‐03‐20 |
| Autologous adipose tissue derived mesenchymal stem cells | Phase 2 | NCT04482413 | Nature Cell Co. Ltd. | 2023‐02‐01 | 2024‐05‐30 |
| Human mesenchymal stem cells | Phase 1 | NCT04040348 | Bernard (Barry) Baumel | 2019‐10‐08 | 2023‐05‐01 |
| Human umbilical cord blood derived mesenchymal stem cells | Not applicable | NCT04954534 | Samsung Medical Center | 2021‐07‐12 | 2022‐01‐31 |
| Lomecel‐B (mesenchymal stem cells derived from bone marrow) | Phase 2 | NCT05233774 | Longeveron Inc. | 2021‐12‐28 | 2023‐09‐29 |
| SNK01 (autologous natural killer cells) | Phase 1 | NCT04678453 | NKGen Biotech, Inc. | 2021‐01‐06 | 2022‐12‐01 |
Abbreviation: NCT#, National Clinical Trial number.